PHVS

Pharvaris N.V. [PHVS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHVS Stock Summary

Top 10 Correlated ETFs

PHVS

Top 10 Correlated Stocks

PHVS

In the News

PHVS Financial details

Company Rating
-
Market Cap
894.76M
Income
-84.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-11.31
Forward P/E
-
PEG
-0.98
P/S
-
P/B
6.26
P/C
-
P/FCF
-10.66
Quick Ratio
9.85
Current Ratio
10.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.04
EPS next Y
-
EPS next Q
-
EPS this Y
60.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.94%
-
-
-
-
SMA20
11.11%
SMA50
17.65%
SMA100
33.33%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-56%
ROC
-0.48%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.93-33.0
52W High
-40.52%
52W Low
+180.43%
RSI
49
Rel Volume
0.28
Avg Volume
110.2K
Volume
30.73K
Perf Week
-5.81%
Perf Month
17.97%
Perf Quarter
7.33%
Perf Half Y
8.93%
-
-
-
-
Beta
-3.113
-
-
Volatility
0.32%, 2.43%
Prev Close
-0.81%
Price
19.63
Change
-1.11%

Something similar

Top by Market Cap
JPM
LLY
ABEC.DE
ABEA.DE
AVGO
Top Correlated ETFs
BTC
DEFI
IBIT
BDRY
RCD
Top Correlated Stocks
FEDU
LBSR
DAL
BKD
AGEN
Similar Market Cap
DCM.NS
NRIX
IBDN
DFIP
HCCI

Company Profile

Healthcare Biotechnology
  • Volume Average 110.2K
  • Market Capitalization 894.76M
  • Employee 70
  • CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.
  • Headquarters Leiden,NL
  • IPO Date 2021-02-05
  • Website https://pharvaris.com

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.